On June 1st, the World Health Organization announced that the new inactivated vaccine "Kierlafor" developed by China Beijing Kexing Zhongwei Biotechnology Co., Ltd. has officially passed the WHO emergency use certification.

WHO Director-General Tan Desai announced at a press conference that Kexing's new covid-19 has been proved to be "safe, effective and quality-guaranteed" and has been included in the WHO's emergency use list. In addition, the easy storage of the vaccine makes it very suitable for resource-poor environments.

According to the opinion of the WHO immunization strategy advisory group, the WHO recommends that Kexing vaccine be used for adults 18 years of age and older, with two doses of vaccinations, with an interval of 2 to 4 weeks. The data shows that the vaccine has an effective rate of 51% in preventing the appearance of covid-19 symptoms, and an effective rate of 100% in preventing severe cases of covid-19 disease and hospitalization.

Although there are few data on the participation of people over 60 in clinical trials of Kexing vaccine, WHO does not recommend setting an upper age limit for the vaccine, because various data indicate that the vaccine may also have a protective effect on the elder.